Literature DB >> 9949339

Databases in the assessment of the effects of drugs during pregnancy.

F Rosa1.   

Abstract

There is limited information on the effects of marketed drugs in pregnant women, largely because premarketing studies are not conducted in this population unless the agent is intended for specific use during pregnancy. Current information on the use of available medications during pregnancy includes 3 types of data: (1) case reports, (2) case-control studies, and (3) cohort studies. Assessments of pregnancy risk related to medication use most commonly involve case reports, and each year the Food and Drug Administration catalogs approximately 1000 suspected adverse drug experiences during pregnancy. The Food and Drug Administration, working with Michigan Medicaid, has developed a database of several hundred thousand pregnancy outcomes. Results of this study for asthma medications used between 1980 and 1992 are presented. However, interpretation of the results is complicated, and substantially more data are required, particularly as new medications become available.

Entities:  

Mesh:

Year:  1999        PMID: 9949339     DOI: 10.1016/s0091-6749(99)70264-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  3 in total

1.  How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.

Authors:  Jørn Olsen; Andrew Czeizel; Henrik Toft Sørensen; Gunnar Lauge Nielsen; Lolkje T W de Jong van den Berg; Lorentz M Irgens; Charlotte Olesen; Lars Pedersen; Helle Larsen; Rolv T Lie; Corinne S de Vries; Ulf Bergman
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants.

Authors:  Bengt Källén; Petra Otterblad Olausson
Journal:  Eur J Clin Pharmacol       Date:  2007-02-06       Impact factor: 2.953

3.  Maternal asthma medication use and the risk of gastroschisis.

Authors:  Shao Lin; Jean Pierre W Munsie; Michele L Herdt-Losavio; Erin Bell; Charlotte Druschel; Paul A Romitti; Richard Olney
Journal:  Am J Epidemiol       Date:  2008-04-23       Impact factor: 4.897

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.